PDCD1 and neoplasm: Based on this mechanism, PD-1/PD-L1 blockade has resulted in considerable improvements in the outcomes of patients with advanced malignancies across a wide range of tumor sites (Brahmer et al., 2015; Sharma et al., 2017b).